Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

Rhea-AI Summary

Charles River Laboratories (NYSE: CRL) and Ziphius Vaccines announced a partnership to manufacture plasmid DNA, a key component for clinical-phase research. The collaboration aims to expedite the development of Ziphius' self-amplifying RNA technology, which promises enhanced protein expression at lower doses. This deal leverages Charles River's expertise in GMP plasmid production, beneficial for Ziphius’ clinical testing and vaccine development timelines. The partnership reflects a growing focus on advanced therapies, particularly in vaccine development.

Positive

• Partnership with Ziphius Vaccines to enhance plasmid DNA manufacturing.
• Utilization of Charles River's GMP expertise accelerates Ziphius' clinical timelines.
• Potential for improved vaccine development through advanced saRNA technology.

Negative

• None.

Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing

WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced an agreement to manufacture starting materials critical to clinical-stage research.

Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, as the saRNA molecule encodes a viral RNA replicase in addition to the sequence of the protein(s) of interest. This mechanism leads to enhanced and prolonged protein expression levels at lower doses compared to conventional mRNA.

Plasmid DNA Manufacturing Services
Plasmid DNA is a critical starting material in the development of many advanced therapies. This collaboration will leverage Charles River’s industry leading expertise in GMP and High Quality (HQ) plasmid DNA production. Utilizing Charles River's custom HQ plasmid offering will benefit Ziphius Vaccines with accelerated timelines without compromising on quality. Charles River, with the acquisitions of Cognate BioServices, Cobra Biologics, and Vigene Biosciences in 2021, has expanded its comprehensive cell and gene therapy portfolio to include CDMO capabilities spanning viral vector, plasmid DNA and cellular therapy production for clinical through to commercial supply.

Approved Quotes

• “We are proud to work with Ziphius Vaccines in their early-stage program. The advancement of saRNA technologies is an exciting avenue for the development of vaccines and therapeutic programs, and we’re looking forward to a successful partnership.” – Kerstin Dolph, Senior Vice President, Global Biologics, Charles River
• “This collaboration with Charles River is an important milestone towards clinical testing and further validation of our vaccine candidates. Charles River’s expertise in plasmid manufacturing made them the best partner for this stage of our saRNA manufacturing program. As we continue the development of our saRNA and carrier technology platform, we’re excited by the potential their scale and efficiency offers.” –Chris Cardon, CEO, Ziphius Vaccines

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Ziphius Vaccines
Ziphius Vaccines is a biopharmaceutical company focused on developing best-in-class vaccines and therapeutics based on its proprietary self-amplifying RNA and carrier technology platforms. The Company’s lead compound ZIP1642 is a COVID-19 vaccine candidate that has been evaluated in preclinical studies. Based in Ghent, Belgium, the Company has a portfolio of next generation vaccine candidates targeting infectious diseases and gene supplementation therapies. For more information, visit www.ziphius.org, and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005117/en/

Investors:

Todd Spencer

Corporate Vice President, Investor Relations

Charles River

781.222.6455

todd.spencer@crl.com

Hendrik Thys

Investor Relations Manager

Ziphius Vaccines

Hendrik.Thys@ziphius.org

Media:

Amy Cianciaruso

Corporate Vice President, Chief Communications Officer

Charles River

781.222.6168

amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.

FAQ

What is the significance of the partnership between Charles River and Ziphius Vaccines?

The partnership focuses on manufacturing plasmid DNA, essential for clinical-stage research, enhancing the development timelines for Ziphius Vaccines' programs.

How does the self-amplifying RNA technology benefit vaccine development?

Self-amplifying RNA technology allows for prolonged protein expression at lower doses, potentially leading to more effective vaccines.

What are plasmid DNA manufacturing services, and why are they important?

Plasmid DNA manufacturing services provide critical materials for advanced therapies, including vaccines and gene therapies.

When was the agreement between Charles River and Ziphius Vaccines announced?

The agreement was announced on a date unspecified in the press release.

What is the stock symbol for Charles River Laboratories?

The stock symbol for Charles River Laboratories is CRL.